Batimastat
Based on 17 publication(s) in Google Scholar
Batimastat is a potent broad spectrum MMP inhibitor with IC50 of 3, 4, 4, 6, and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3, respectively.
For research use only. We do not sell to patients.
- Purity: 98.92%
- CAS No.: 130370-60-4
- Formula: C23H31N3O4S2
- Molecular Weight:477.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Angiogenesis-Related Compound Library
HY-L088
-
Human Metabolite Library
HY-L123
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Pain-Related Compound Library
HY-L139
-
Protease Inhibitor Library
HY-L147
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Batimastat
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- J Neuroinflammation. 2019 Nov 28;16(1):242. [Abstract]
- Int J Biol Sci. 2022 May 1;18(8):3167-3177. [Abstract]
- Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
- Osteoarthritis Cartilage. 2019 Jan;27(1):148-157. [Abstract]
- ACS Environ Au. 2025 Aug 5;5(6):573-582. [Abstract]
- Cell Rep. 2019 Oct 15;29(3):603-616.e5. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Virulence. 2026 Mar 25:2649986. [Abstract]
- Biomacromolecules. 2026 Feb 9;27(2):1547-1557. [Abstract]
- Life Sci. 2022.
- Mol Cell Endocrinol. 2020 Dec 1;518:111005. [Abstract]
- Endocrine. 2021 May;72(2):529-538. [Abstract]
- Physiol Rep. 2025 Nov;13(21):e70614. [Abstract]
- bioRxiv. 2026 Jun 3:2026.06.01.728985. [Abstract]
- bioRxiv. 2020 Jun.
- San Diego State University. 2019 Jun.
Customer Validation & Images
-
Cell Migration/Invasion Assay
-
Cell Imaging/Staining
-
WB
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
IC50: 3 nM (MMP-1), 4 nM (MMP-2), 4 nM (MMP-9), 6 nM (MMP-7), 20 nM (MMP-3)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Sf9 | IC50 |
0.013 μM
Compound: BB-94 (batimastat)
|
Inhibition of human matrix metalloprotease-2 expressed in Sf9 insect cells
Inhibition of human matrix metalloprotease-2 expressed in Sf9 insect cells
|
[PMID: 15582436] |
| Sf9 | IC50 |
0.025 μM
Compound: BB-94 (batimastat)
|
Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells
Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells
|
[PMID: 15582436] |
Batimastat (BB-94) is a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. Batimastat inhibits gelatinases A and B with IC50 values of 4 nM and 10 nM, respectively. The IC50 with the structurally similar collagenase Ht-d is 6 nM, which is comparable with values for MMP-1 (3 nM), MMP-8 (10 nM), and MMP-3 (20 nM)[2]. CD30 shedding from the cell line Karpas299 can effectively be blocked by the hydroxamic acidbased metalloproteinase inhibitor Batimastat (BB-94, IC50=230 nM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 130370-60-4
-
Appearance Solid
-
Molecular Weight 477.64
-
Formula C23H31N3O4S2
-
Color White to off-white
-
SMILES
O=C(N[C@@H](CC1=CC=CC=C1)C(NC)=O)[C@H](CC(C)C)[C@H](CSC2=CC=CS2)C(NO)=O
-
Synonyms
BB94
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (17)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
J Neuroinflammation
The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke. [Abstract]2019 Nov 28;16(1):242. PMID: 31779652
Batimastat purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2019 Nov 28;16(1):242. [Abstract]
Batimastat (MI) (50 ng/mL) supplement to the ACM increased Claudin-5, occludin, and ZO-1 levels of bEnd.3 cells.
Batimastat purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2019 Nov 28;16(1):242. [Abstract]
In the groups cultured with ACM from astrocytes exposed to OGD+RO, the additional Batimastat (MI) (50 ng/mL) treatment increased the TEER of the cell monolayer.
-
Int J Biol Sci
2022 May 1;18(8):3167-3177. PMID: 35637967
Batimastat purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 May 1;18(8):3167-3177. [Abstract]
Batimastat (BB-94) (10 μM; 24 h) abrogated the promotion of HepG2 and HeLa cells invasion by SNCG.
-
Cell Death Dis
TGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis. [Abstract]2025 Aug 6;16(1):592. PMID: 40770187
Batimastat purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
Representative images of migration capacity (boyden chamber assay) for L3.6pI cells treated or not with Batimastat (BB-94) (25 nM).
-
Osteoarthritis Cartilage
IL-37 diminishes proteoglycan loss in human OA cartilage: donor-specific link between IL-37 and MMP-3. [Abstract]2019 Jan;27(1):148-157. PMID: 30201492
Batimastat purchased from MedChemExpress. Usage Cited in: Osteoarthritis Cartilage. 2019 Jan;27(1):148-157. [Abstract]
MMP-3-inhibitor Batimastat (1 μM; 6 h) significantly reduced the sGAG release from human OA explants.
-
ACS Environ Au
Machine Learning-Assisted Recognition of Environmental Sulfur-Containing Chemicals in Nontargeted Mass Spectrometry Analysis of Inadequate Mass Resolution. [Abstract]2025 Aug 5;5(6):573-582. PMID: 41277996 -
Cell Rep
Metalloprotease-Dependent Attenuation of BMP Signaling Restricts Cardiac Neural Crest Cell Fate. [Abstract]2019 Oct 15;29(3):603-616.e5. PMID: 31618630 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Virulence
Monkeypox virus replication and host response in vaginal and ectocervical epithelial cells. [Abstract]2026 Mar 25:2649986. PMID: 41880196 -
Biomacromolecules
Dual Enzyme-Responsive Zwitterionic Peptide for High Cancer Selectivity via Intralysosomal Self-Assembly. [Abstract]2026 Feb 9;27(2):1547-1557. PMID: 41562291 -
-
Mol Cell Endocrinol
Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway. [Abstract]2020 Dec 1;518:111005. PMID: 32877753 -
Endocrine
125I-Angiotensin 1-7 binds to a different site than angiotensin 1-7 in tissue membrane preparations. [Abstract]2021 May;72(2):529-538. PMID: 33415576 -
Physiol Rep
TRPC6 effects on albumin permeation, nephrin shedding, and apoptosis in podocytes: Role of calcineurin and metalloproteases. [Abstract]2025 Nov;13(21):e70614. PMID: 41165237 -
bioRxiv
ProNotch converts extracellular protease activity into programmable transcriptional outputs. [Abstract]2026 Jun 3:2026.06.01.728985. PMID: 42282718 -
-
Solvent & Solubility
DMSO : 25 mg/mL (52.34 mM; ultrasonic and warming and heat to 70°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (10.47 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.23 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Mice[5]
Six-weeks-old female BALB/c mice are used. Mice are treated i.p. with Batimastat (BB-94, 50 mg/kg) 1 h before and 24 h post-infection. Batimastat is suspended at 50 mg/mL in DMSO and stored frozen at -20°C. Prior to use, it is diluted 20-fold in phosphate buffered saline (PBS), and 500 μL are injected into animals. Control mice are injected with 500 μL of 5% DMSO in PBS. Animals are sacrificed 48 h after i.c. challenge.
Rats[6]
Female Sprague-Dawley rats are administered a single physiological dose of E2 (40 μg/kg in a 0.9% NaCl, 0.4% EtOH vehicle) by intraperitoneal (i.p.) injection at the indicated time intervals prior to tissue collection at necropsy. This in vivo dose level of E2 has been shown to induce changes in uterine wet weight, tissue architecture, and gene expression characteristic of estrogen receptor activation. For all other experiments, animals are i.p. administered a single 40 μg/kg bolus of E2 4 h prior to tissue harvest, while control animals receive vehicle only in all studies. Batimastat is administered i.p. at a dose level (40 mg/kg in a 1× PBS, 0.1% Tween-20 vehicle) shown to be effective at inhibiting MMPs in vivo 4 h prior to E2 or saline control.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yin Z, et al. Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab. 2012 Jul 1;303(1):E55-70. [Content Brief]
[2]. Botos I, et al. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2749-54. [Content Brief]
[3]. Hansen HP, et al. Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int J Cancer. 2002 Mar 10;98(2):210-5. [Content Brief]
[4]. Giavazzi R, et al. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin Cancer Res. 1998 Apr;4(4):985-92. [Content Brief]
[5]. Ricci S, et al. Inhibition of matrix metalloproteinases attenuates brain damage in experimental meningococcal meningitis. BMC Infect Dis. 2014 Dec 31;14:726. [Content Brief]
[6]. Russo LA, et al. Regulated expression of matrix metalloproteinases, inflammatory mediators, and endometrial matrix remodeling by 17beta-estradiol in the immature rat uterus. Reprod Biol Endocrinol. 2009 Nov 4;7:124. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0936 mL | 10.4681 mL | 20.9363 mL | 52.3407 mL |
| 5 mM | 0.4187 mL | 2.0936 mL | 4.1873 mL | 10.4681 mL | |
| 10 mM | 0.2094 mL | 1.0468 mL | 2.0936 mL | 5.2341 mL | |
| 15 mM | 0.1396 mL | 0.6979 mL | 1.3958 mL | 3.4894 mL | |
| 20 mM | 0.1047 mL | 0.5234 mL | 1.0468 mL | 2.6170 mL | |
| 25 mM | 0.0837 mL | 0.4187 mL | 0.8375 mL | 2.0936 mL | |
| 30 mM | 0.0698 mL | 0.3489 mL | 0.6979 mL | 1.7447 mL | |
| 40 mM | 0.0523 mL | 0.2617 mL | 0.5234 mL | 1.3085 mL | |
| 50 mM | 0.0419 mL | 0.2094 mL | 0.4187 mL | 1.0468 mL |
Powered by Bioz